logo
[Copy] The 8 Best At-Home Laser Hair Removal Devices, Based On Expert Advice

[Copy] The 8 Best At-Home Laser Hair Removal Devices, Based On Expert Advice

Forbes23-05-2025
Laser hair removal can make your grooming routine much more efficient; unlike shaving, this method damages hair follicles to reduce growth over time, ultimately giving more long-term results. After speaking with experts and gathering personal recommendations from Forbes Vetted testers, we landed on the eight best at-home laser hair removal devices, all of which are FDA-cleared. Our top pick overall is the Braun Silk Expert Pro 5, which has 10 intensity levels and four interchangeable caps for full-body treatment. If you have coarse hair, we recommend the ultra-efficient Nood Flasher 2.0, which can offer visible results in as little as three weeks.
According to dermatologist Dr. Ramya Garlapati, these gadgets work similarly to in-0ffice laser treatments, but when compared to them, 'the energy level of the at-home lasers is much lower.' Devices designed for home use are commonly IPL (intense pulsed light) tools—many of which are featured in our roundup—which work to achieve similar results as a diode laser does. In addition to providing a convenient alternative to going in for appointments, these hair removal tools can also help with upkeep. (Keep in mind: If you do opt to do this at home, you may need more sessions to see lasting results.) From luxury picks to affordable options, here are the best at-home laser hair removal devices for zapping unwanted body hair.
Forbes Vetted readers get 15% off on first purchases at Braun using code FORBES15.
Flashes: 400,000 | Laser type: IPL | Intensity levels: 10 | FDA-cleared: Yes
Pros:
Cons:
Braun's Silk Expert Pro 5 has several features that will help you get rid of unwanted hair more efficiently. It features a gliding mode for quickly treating large areas, like the legs, and a stamping mode for hard-to-reach areas, like the bikini line. It also has SensoAdapt technology, which automatically adjusts the flash intensity for safe use on skin. There are 10 intensity levels total, and it's possible to treat both legs in just five minutes at the lowest energy setting. According to the brand's website, results can be seen in as little as four weeks with regular use. The set includes four attachment caps that allow you to safely target different areas of your body, including your armpits and face. There's also a Venus razor for touch-ups.
What the reviews say: 'I've used it for two months so far and have seen good results—quite a reduction of hair,' says one Braun customer. 'I have tried so many different machines and this one is the best so far. My underarms are the hardest thing, and there are fewer hairs and they are so much thinner.' However, some users note that completing a full-body treatment with this device is a bit tedious.
The 2024 Forbes Vetted Best Product Awards are here: Explore our 150 top-recommended items across categories after extensive research and testing.
Forbes Vetted readers get $10 off the Flasher 2.0 (and all purchases at Nood) by entering code FORBES10 at checkout.
Flashes: 600,000 | Laser type: IPL | Intensity levels: 3 | FDA-cleared: Yes
Pros:
Cons:
This device offers a larger treatment window, meaning you only need about 10 minutes per session. Nood's technology also includes one of the highest-intensity lamps that targets hair at the root, without causing sensitivity and redness—even on coarse hair. The device is so effective that you'll see results within as little as three weeks and will notice more permanent hair removal in six to eight weeks. You can switch between three modes, depending on your skin's sensitivity. It's best suited for very fair skin to light brown skin, but may not be as effective or safe for darker skin tones. For more info, read our in-depth Nood review here.
What our testers say: 'The Flasher 2.0 has a thoughtful, compact design that fits nicely in the hand, and it's lightweight enough that lengthier IPL sessions don't feel like a chore,' says Forbes Vetted contributor Jessica Timmons. 'Our panel of testers appreciated the privacy, pricing and convenience of using it at home compared to in-office laser hair removal.'
Flashes: 300,000 | Laser type: IPL | Intensity levels: 6 | FDA-cleared: Yes
Pros:
Cons:
Most at-home laser hair removal devices come with larger price tags, but this one from RoseSkinCo. makes our list as the best value pick. Although it's more affordable, the device doesn't falter when it comes to results; you may start noticing positive benefits as soon as three weeks, so long as you use the device once per week. (Long-term hair removal can be expected after 12 uses, over the course of six to 12 weeks.) It offers six intensity levels and is suitable to use all over your body, including your armpits, legs, face and bikini area. Note that the device shouldn't be used above the cheekbones or on the inner part of the bikini area.
What the reviews say: 'It's honestly a great investment,' says one RoseSkinCo. reviewer. 'I've only been using the Lumi for five weeks, but there are already spots on my legs where the hair has stopped growing. It's super easy and quick to use, and it's so nice that there is no pain involved.' However, some reviewers with dark brown or black hair say the device takes several weeks to begin producing visible results.
Flashes: Unlimited | Laser type: IPL | Intensity levels: 10 | FDA-cleared: Yes
Pros:
Cons:
This recently upgraded device glides over large and small areas to provide lasting hair removal results. The Pure Adapt's head automatically adjusts to the contours of your body, preventing missed spots and unwanted burns. There are three comfort modes (Power, Speed and Gentle) that allow you to tailor the device to your targeted areas. Its smart sensor calibrates the ideal IPL for your specific skin and hair type, and each treatment takes about 10 minutes. The device is safe to use on all areas of your body, as well as your face. According to the brand, you can expect to see visible results in just two weeks.
What our editors say: 'I've been using this device for about three weeks, and it's the definition of user-friendly: You just plug it in, aim it at your target area and press a button,' says managing editor Emmy Favilla. 'It's minimally painful, and comfortable to hold and wield. While hair is re-growing, it does seem like it's coming in less coarse, which is a great sign.'
Flashes: 500,000 | Laser type: OPT | Intensity levels: 6 | FDA-cleared: Yes
Pros:
Cons:
The Jovs Venus Pro has several elements that make it worth the investment. It has a 180-degree rotating head (for better precision), a skin-cooling feature (for added comfort) and useful attachments, like an LED option that also helps reduce visible signs of aging. Unlike the other options on this list, this model uses optimum pulsed light (OPT) technology, which is a more enhanced version of IPL that may provide more effective results. It has six function modes and intensity levels for customized treatment on your legs, underarms, face and bikini lines. A full-body treatment can be completed in around seven minutes, and visible results can be noticed in as soon as four weeks.
What the reviews say: Fans of this device praise its unique, streamlined shape, which many say allows access to hard-to-reach areas. 'This is the most ergonomic laser hair removal device that I've ever tried, and I've tried a bunch,' says one Walmart customer. 'The fact that the light source head can pivot is huge.' However, some reviewers say they expected more effective results given the high price tag.
Flashes: Unlimited | Laser type: IPL | Intensity levels: 3 | FDA-cleared: Yes
Pros:
Cons:
The Ulike Sapphire Air 3 is so easy to use, you may feel emboldened to use it on your entire body. Its sapphire ice-cooling technology makes the process as painless as possible, while the thumb-free auto glide mode allows you to cover large areas of your body in one fell swoop. The device delivers flashes every 0.7 seconds, and a full-body treatment can take as little as 12 minutes. You can expect to see results in about three weeks, with treatment frequency starting at three times a week and gradually reducing to every month.
What the reviews say: Over 1,400 customers give this model a 5-star rating. 'I've had full body laser professionally done and this works just as well, in fact better in a few areas,' says one Amazon customer. 'It's been great on my stubborn areas like my knees and I'm finally lasering my arms now as well. On top of actually working, it's not kidding about being pain-free.'
Flashes: Unlimited | Laser type: IPL with RF | Intensity levels: 3 | FDA-cleared: Yes
Pros:
Cons:
The Iluminage Touch is a laser for the the face and body that uses intense pulsed light (IPL) and radio frequency (RF) to gently zap away unwanted hair. It's this combination that makes this pick safe for darker shades of skin—in fact, it's the first at-home laser that's cleared by the FDA to use on all skin tones. The device features three energy levels that can be used on a wide range of hair colors, including blonde, dark blonde and red hair. It also comes with a precision adaptor and an epilator attachment to optimize treatments. The Iluminage Touch also provides results fast—users can expect to see a noticeable decrease in hair growth after just two treatments, and full results in seven weeks.
What the reviews say: 'I have been using this for five weeks now and am very pleased with the results,' says one Nordstrom customer. 'I'd say easily 75% of my most stubborn black and coarse hair is gone. On my not so stubborn hair I have noticed about a 90 to 95% reduction. For the hairs that are growing back still, they are much more fine and lighter in color.' However, a portion of customers with coarse hair report that this machine's laser wasn't strong enough to deliver the results they wanted.
Flashes: 600,000 | Laser type: eHPL (galvanic and optical energy) | Intensity levels: 5 | FDA-cleared: Yes
Pros:
Cons:
This upgraded Silk'n device targets follicles on a wider range of skin tones than its previous iteration. Its enhanced Home Pulsed Light technology (which is a safer, home-friendly version of IPL) now uses galvanic energy to helps its light reach hair follicles more deeply—and twice as fast than the previous model. Since the laser uses energy from a bulb instead of thermal heat, it's designed to fit comfortably in the palm of your hand, making it our top pick for travel. You can expect to see noticeable results after three to four treatments, and full results after eight. It's also safe for use on your underarms, legs, bikini lines and face, and has five intensity settings to customize your treatment.
The Forbes Vetted team has researched, written and published dozens of beauty and grooming stories, relying on our personal expertise as well as thorough insight from qualified professionals.
When compiling this list of the best at-home laser hair removal devices, we considered the top options on the market at different price points and capabilities.
If you're looking for an at-home laser hair removal device that provides results on par with a professional treatment, there are several factors to consider. Here's what to keep in mind.
Most at-home laser hair removal devices use intense pulsed light (IPL) therapy to treat unwanted body hair. However, some devices such as the Jovs Venus Pro II use optimal pulse technology (OPT), which is an enhanced version of IPL that can penetrate the skin more deeply and therefore may be more effective. A select few devices (including the Iluminage Touch) combine IPL with radio frequency (RF) heat energy, which reduces IPL intensity so it can be used across a wider range of skin tones.
You can think of the number of flashes (also known as pulses) as the lifespan of the laser. It determines how long you can use the tool before it wears out. In many cases, you can achieve the results you want with one device. According to cosmetic dermatologist Dr. Ava Shamban, areas such as the lip and face generally need about 25 to 50 flashes; the underarm or bikini line might need up to 200 flashes; larger areas like the legs may need 500 to 600 flashes each; the chest or back may require 700 or even 800 flashes.
Laser hair removal devices aren't one size fits all. 'Some may not be advisable for darker skin tones, which have a higher chance for issues such as burning or hyperpigmentation,' says Shamban. 'Usually, lighter skin with darker hair is the best combination, but some can be used on all skin tones and types.' (See the Iluminage Touch, our pick for dark skin tones.) Most devices have multiple intensity levels as well; a higher intensity level will deliver faster results, but it may aggravate sensitive skin. Opting for a device with a skin-cooling feature can remedy some of the pain and irritation caused by more powerful treatments.
It's a good idea to keep your desired treatment area in mind when selecting an at-home laser hair removal device, especially if you want to cover larger parts on the body. An automatic flashing feature (like the one found on the Ulike Sapphire Air 3) allows you to cover more surface area without having to hold down a button. Some devices, like the Braun Silk Expert Pro 5, include different detachable laser heads that allow you to target specific places that are hard to reach, like the bikini line.
'Laser hair removal is a treatment in which the hair follicle is permanently destroyed, and this prevents hair growth,' says Garlapati. This method is an excellent solution if you're tired of frequent shaving, waxing or other more temporary grooming options. At-home laser devices work in the same way as ones found in professional establishments, but at lower frequencies. 'As a result, these treatments require more sessions to show an improvement, and they may not be as effective,' she says. That's why it's important to be patient and consistent with your efforts, as it may take several weeks before you notice any change in your hair growth.
Safety is often a concern when using one of these laser tools. 'Any device purchased for home usage should be FDA-approved or cleared,' says Shamban. This information should be indicated or marked on the device's packaging or instructions. It's also important to pay attention to the list of usages, as some versions are only safe to use on certain areas. In addition, Garlapati explains that 'there is a risk of burning your skin and causing hyperpigmentation if you do too many passes.' That's why it's important to diligently follow the directions depending on the area that you want to treat.
After comparing all eight models on our list, one stood out as the clear winner: The Braun IPL Silk Expert Pro 5 is the best laser for hair removal at home, thanks to its wide range of intensity levels and variety of attachments for different parts of your body. However, everyone's hair removal needs are different. If you have coarse hair, we recommend the Nood Flasher 2.0, while those with darker skin tones should look into the Illuminage Touch.
Yes, you should shave before you begin using a laser hair removal device; according to Nood, this should ideally be 12 to 24 hours before you apply the laser to your skin. Shaving can be done with either a manual razor or an electric razor, but keep in mind that a manual razor will provide a closer shave and reduce the risk of the laser burning your hairs. If you plan on using your IPL device to remove facial hair, you should stick to dermaplaning the area rather than shaving.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bausch + Lomb board members resign after Icahn agreement ends
Bausch + Lomb board members resign after Icahn agreement ends

Yahoo

time13 minutes ago

  • Yahoo

Bausch + Lomb board members resign after Icahn agreement ends

(Reuters) -Bausch + Lomb said on Monday Brett Icahn and Gary Hu have resigned from its board of directors after the termination of the agreement with billionaire Carl Icahn and some of his affiliates. The agreement, dated June 21, 2022, ended after the Icahn group's net long position in Bausch Health Companies, Bausch + Lomb's parent, fell below the required threshold. On Friday, Bausch Health said Paulson Capital, along with certain affiliates and managed funds, increased their position in the company and acquired about 34.7 million common shares previously held by the Icahn Group. In April, Carl Icahn had built an economic interest covering about 34% of Bausch Health's shares. Sign in to access your portfolio

Seattle health-tech startup Kevala acquired by Residex in bid to enhance senior care with AI
Seattle health-tech startup Kevala acquired by Residex in bid to enhance senior care with AI

Geek Wire

time14 minutes ago

  • Geek Wire

Seattle health-tech startup Kevala acquired by Residex in bid to enhance senior care with AI

GeekWire's startup coverage documents the Pacific Northwest entrepreneurial scene. Sign up for our weekly startup newsletter , and check out the GeekWire funding tracker and venture capital directory . Todd Owens, CEO of Seattle-based health-tech startup Kevala. (Gavin Haag Photo) Seattle-based Kevala, a startup that helps healthcare facilities find and manage workers, has been acquired by Residex, a Denver company that also uses AI to manage records and more for senior living communities. Terms of the deal were not shared in a news release on Monday. Kevala was spun out of Seattle's Pioneer Square Labs in 2020. The company raisied $4 million in January 2021 and another $12.1 million in February 2022. Co-founder and CEO Todd Owens previously led staffing company TalentWise, which was acquired by Sterling Talent Solutions; was CEO at Appuri (acquired by DocuSign); and was CEO at Azuqua (acquired by Okta). According to Residex, the acquisition will strengthen the company's position in the senior care technology market by adding staffing optimization to platform. Residex uses AI to help manage resident health records, medication administration, care planning, assessments, and clinical documentation. Kevala's software, called Quin, enables healthcare facilities to schedule workers, organize the labor pool and track caregiver credentials. 'This acquisition validates our vision of using AI to solve the industry's most pressing operational challenge of ensuring topline workforce management,' Owens said in a statement. By combining Quin's workforce intelligence with Residex's clinical expertise, we're creating a powerful ecosystem that ultimately enhances the quality of life for residents.' As of April of this year, Kevala employed 28 people and had raised $21 million. Related:

Time is running out for kids with a rare disease, parents say, unless the FDA acts
Time is running out for kids with a rare disease, parents say, unless the FDA acts

NBC News

time15 minutes ago

  • NBC News

Time is running out for kids with a rare disease, parents say, unless the FDA acts

Gilbert Dryden probably only has enough medication to get him through the end of October, his mother, Madison, figures. Seven-month-old Gilbert has a rare genetic condition called Barth syndrome, one that can have dire consequences, like heart failure, extreme muscle weakness and a dramatically reduced life expectancy. Children who die early often don't see their fifth birthday. Two infant deaths were reported within the past week, according to the Barth Syndrome Foundation. What's been keeping Gilbert alive and functioning relatively well, according to his family, is an experimental drug called elamipretide, made by Stealth BioTherapeutics. Small studies have suggested it's safe and effective in treating the ultra-rare illness. Just 150 people in the U.S. have the condition. 'Our kids are dying. We have seen that this drug works,' said Kate McCurdy, a co-founder of the Barth Syndrome Foundation. 'This drug totally saves the lives of babies.' After a more than decade-long process to bring the drug to market, the treatment's approval has repeatedly hit roadblocks with the Food and Drug Administration. One setback occurred in the spring, when an FDA inspection found problems at a Stealth manufacturing facility. The problems weren't made public, but apparently weren't egregious enough to warrant regulatory action. The company said the issues have been resolved. In late May, after an advisory panel voted earlier (in October 2024) to recommend the therapy, the FDA declined to approve it. The agency didn't reveal why. An ultra-rare disease like Barth syndrome with an ultra-small population of patients who can be tested for clinical efficacy faces barriers for FDA drug approval. There aren't enough patients to do robust, randomized clinical trials, McCurdy said. 'It is virtually impossible to conduct trials that yield data that are conclusive beyond a reasonable doubt. Statistically, you just can't do that,' she said. Weeks later and following a meeting between Needham, Massachusetts-based Stealth and the FDA in late June, the real bombshell came: The company said the agency informed Stealth on Aug. 4 that it would need to resubmit a new drug application — for the third time. It could use a special pathway called 'accelerated approval' in that submission, but the manufacturing issue would extend the timeline to review elamipretide for at least another six months, according to the company. Stealth said that no additional clinical data or safety data was requested. But without any course correction in the process, the private company could run out of money. The delay is devastating to families like the Drydens. 'When we heard this news, we immediately went to the fridge to count how many vials we have left, because that's how long we have this medication. That's the only guarantee we have right now that Gilbert is not going to die,' said Madison Dryden, 35, of Aurora, Colorado. 'It's the highest level of desperation.' On Monday, Stealth announced that it did submit its third application for approval of elamipretide — asking for an accelerated pathway under a significantly tighter timeline than what the agency initially recommended. What is Barth syndrome? Madison Dryden and her husband, Andrew, weren't sure what was wrong with Gilbert in the hours and days after his Christmas Eve birth in 2024. 'His heart function was so low. He was so sick, his body and his feet were purple, his hands were purple,' Dryden said. 'He couldn't eat.' Gilbert was admitted to the neonatal intensive care unit and received lifesaving care as doctors urgently tried to figure out a diagnosis. Within a matter of days, Dryden said, Gilbert was airlifted to Children's Hospital Colorado with a heart that was struggling to adequately pump blood. The underlying cause was soon revealed: Barth syndrome. The disease impairs cells' mitochondria, which are kind of like tiny batteries that generate energy for cells to function correctly. The chromosomal disorder almost exclusively affects boys. Roughly 85% of early deaths occur before age 5. Those who survive longer are usually given heart medications and may need a heart transplant. Kids with Barth syndrome often rely on drugs like beta blockers and ACE inhibitors to keep their hearts functioning as well as possible. Gilbert was fortunate, at least initially. He found a lifeline through access to the treatment from Stealth. Elamipretide, a daily injection, works by helping to repair the damaged mitochondria. In clinical trials, like the one the Drydens participated in, patients showed a 45% improvement in muscle strength and a 40% improvement in heart function, according to the drugmaker. Most participants have safely remained on the drug for over eight years. In October 2024, an advisory committee to the FDA voted 10-6 in support of the therapy, paving the way for the agency to clear the first drug to treat Barth syndrome. The FDA isn't required to follow the advisory committee's guidance, but it almost always does. A spokesman for the Department of Health and Human Services, which oversees the FDA, wrote in an email that the 'FDA did carefully consider the advice of the advisory committee members, including their rationale for their vote. While there is often a high rate of agreement between FDA and advisory committee recommendations,' the spokesman said, 'there is not always concordance.' 'Compelling medical need' for approval After the advisory committee's recommendation, the FDA's rejection was unexpected. 'It is a small sample size,' said a former FDA official who was involved in the drug approval process. The person asked not to be identified in order to speak freely. But the former official was quick to point out that given the advisory committee recommendation for approval, the 'incredibly compelling medical need' of those living with Barth syndrome and the small sample of individuals who seemed to have benefited from the treatment, it certainly appeared that elamipretide was going to make it across the finish line. A lack of continuity in leadership, however, may have added to the already difficult challenge of guiding the treatment through the final hurdles, the former official said. The FDA has seen many top officials leave the agency in recent months. 'Those who have taken over are not as familiar, or perhaps it'd be more appropriate to say they're inexperienced with how one does drug approvals, how one drives things forward, and they're also somewhat fearful of the current environment,' the former official said. 'And I think that's led to an adverse outcome for some of these rare disease products.' The HHS spokesperson didn't immediately respond to a request Monday for comment about the agency's rejection of the drug or leadership issues. A Wall Street Journal Op-Ed recently offered a scathing evaluation of what's happening at the FDA, questioning whether the agency and Commissioner Marty Makary's stated goal of accelerating lifesaving drugs is matching the reality of their actions. The Journal said that there were averages of 52 annual drug approvals under the first Trump administration and 48 under President Joe Biden, but 'there have been only 22 in the first seven months of this year,' projecting to just 38 for the year. Elamipretide was cited in the Journal piece as a casualty of the current environment. The former FDA official pointed out that the treatment hit stumbling blocks under the previous administration, as well, but it was headed in the right direction. 'Now it feels like a hot potato that's been just thrown around,' the former official said. 'And this is just not right. It's just not right.' Families left with few alternatives The Drydens say the FDA decision pulled the rug out from underneath them — and many other families. Dr. Kathryn Chatfield, Gilbert's doctor and a specialist in pediatric cardiology and genetics at Children's Hospital Colorado, said the FDA's inaction leaves families with few alternatives. 'We just don't know what's going to happen,' Chatfield said. 'We're going to have to watch them really closely because they're at risk for recurrence of heart failure and rehospitalization and potentially decompensation to the point where they have to live in the hospital until they could get a heart transplant.' A transplant addresses the heart problem but doesn't alleviate ongoing muscular and skeletal problems. 'I can't be OK with sacrificing my child's life for a bureaucratic process,' Madison Dryden said. The latest hurdle to approval has Barth syndrome families and advocates alike, including some members of Congress, looking for more information and answers. 'Time is of the essence here, and we need to get these drugs to these patients as soon as possible,' said Rep. Buddy Carter, R-Ga., a member of the Energy and Commerce subcommittee on health. Carter spoke to NBC News days before the FDA requested a resubmission in early August and said he'd sent a letter to the agency asking for 'clarity' on elamipretide. 'There aren't that many options out there,' he said. 'In fact, for Barth Syndrome, this elamipretide is really the only drug that we know of that works.' Carter said that there are six families in Georgia alone he's been in contact with who have a loved one with the rare disease. He's hopeful that an 'accelerated pathway' request might prove a viable option for the families and for the company to continue its research. After the recent FDA decision, Carter told NBC News in a statement that he's 'disappointed' with the recommendation 'now that all issues appear to be resolved.' Carter said he's continuing to put pressure on the FDA and that 'patients will suffer with further delays.' He also acknowledged that the economics of a private company, like Stealth, attempting to continue developing a drug for such a small population of patients would be exceedingly difficult without FDA backing. He said he feels deeply for the families in the middle of a terrifying ordeal. 'I'd be calling everybody I could (too), making sure that my child or my grandchild had this medication,' he said in an interview. Madison Dryden and her husband are left with what they call a 'giant unknown' in the absence of approval, struggling for an explanation for their 7- and 3-year-old daughters as families are in a race against time to keep loved ones alive. 'They know that somebody is not giving permission for Gilbert to have his medicine, and that they keep saying no, and they're our kids — like they can't lose … we can't have them lose their baby brother to this,' she said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store